119th Congress · introduced in the House · Aug 19, 2025
Joe Fiandra Access to Home Infusion Act of 2025
Official title from Congress.gov
Latest action (Dec 10, 2025): Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 41 - 0.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Aug 19, 2025)
Joe Fiandra Access to Home Infusion Act of 2025
This bill provides for Medicare coverage of certain home infusion drugs that are administered by health care professionals at a beneficiary’s home.
Specifically, the bill provides for coverage of external infusion pumps and associated home infusion drugs for which (1) the prescription requires that the drug be administered by or under the supervision of a health care professional, (2) a qualified home infusion therapy supplier administers or supervises the administration of the drug at the beneficiary's home, and (3) the prescription requires that the drug be infused at least 12 times per year in a manner that requires the use of an external infusion pump.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 41 - 0.
Committee Consideration and Mark-up Session Held
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Health care coverage and access · Health technology, devices, supplies · Home and outpatient care · Medicare · Prescription drugs
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
14 citations.
CHIESI USA, INC. · lobbying firm or registrant: SPLITOAK STRATEGIES LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Medicare/Medicaid
$60,000
Paid to lobbying firm
Implementation of HR 4993 the Joe Fiandra Access to Home Infusion Act, including issues in CMS-1828-P; Promoting US competitiveness while ensuring continued patient access to lifesaving…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ALNYLAM PHARMACEUTICALS, INC. · lobbying firm or registrant: ALNYLAM PHARMACEUTICALS, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$470,000
Spent on own lobbying
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ALNYLAM PHARMACEUTICALS, INC. · lobbying firm or registrant: ALNYLAM PHARMACEUTICALS, INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$450,000
Spent on own lobbying
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHIESI USA, INC. · lobbying firm or registrant: SPLITOAK STRATEGIES LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Medicare/Medicaid
$60,000
Paid to lobbying firm
Implementation of HR 4993 the Joe Fiandra Access to Home Infusion Act, including issues in CMS-1828-P; Promoting US competitiveness while ensuring continued patient access to lifesaving…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
WELLSKY · lobbying firm or registrant: DB3, LLC (FKA THE DASCHLE GROUP)
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 21, 2026 · issue area: Health Issues
$90,000
Paid to lobbying firm
…R.5142, Home Health Stabilization Act of 2025; H.R.4313/S.2237, Hospital Inpatient Services Modernization Act; H.R.4206/S.1261, CONNECT for Health Act of 2025; H.R.4993, Joe Fiandra Access to Home Infusion Act of 2025.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHIESI USA, INC. · lobbying firm or registrant: SPLITOAK STRATEGIES LLC
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
HR 4993 the Joe Fiandra Access to Home Infusion Act; Promoting US competitiveness while ensuring continued patient access to lifesaving medicines; HR 7148 the Consolid…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ALNYLAM PHARMACEUTICALS, INC. · lobbying firm or registrant: ALNYLAM PHARMACEUTICALS, INC.
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Medicare/Medicaid
$430,000
Spent on own lobbying
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
WELLSKY · lobbying firm or registrant: DB3, LLC (FKA THE DASCHLE GROUP)
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 21, 2026 · issue area: Health Issues
$90,000
Paid to lobbying firm
…lth Pledge; H.R.5142, Home Health Stabilization Act of 2025; H.R.4313, Hospital Inpatient Services Modernization Act; H.R.4206, CONNECT for Health Act of 2025; H.R.4993, Joe Fiandra Access to Home Infusion Act of 2025
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHIESI USA, INC. · lobbying firm or registrant: SPLITOAK STRATEGIES LLC
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 21, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
HR 4993 the Joe Fiandra Access to Home Infusion Act; Promoting US competitiveness while ensuring continued patient access to lifesaving medicines
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ALNYLAM PHARMACEUTICALS, INC. · lobbying firm or registrant: ALNYLAM PHARMACEUTICALS, INC.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Medicare/Medicaid
$390,000
Spent on own lobbying
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
UCB, INC. · lobbying firm or registrant: UCB, INC.
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 17, 2026 · issue area: Health Issues
$350,000
Spent on own lobbying
HR 4993 - Joe Fiandra Access to Home Infusion Act of 2025 HR 4317 - PBM Reform Act of 2025
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ALNYLAM PHARMACEUTICALS, INC. · lobbying firm or registrant: ALNYLAM PHARMACEUTICALS, INC.
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 21, 2025 · issue area: Medicare/Medicaid
$390,000
Spent on own lobbying
Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHIESI USA, INC. · lobbying firm or registrant: SPLITOAK STRATEGIES LLC
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
HR 4993 the Joe Fiandra Access to Home Infusion Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
UCB, INC. · lobbying firm or registrant: UCB, INC.
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Pharmacy
$340,000
Spent on own lobbying
HR 4993 - Joe Fiandra Access to Home Infusion Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing